APL 400-047
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
HIV Infections
Phase 1
A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
CompletedNCT00001088
Start: 1997-07-31End: 2001-02-28Target: 40Updated: 2008-09-29
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
CompletedNCT00001090
End: 1999-10-31Target: 36Updated: 2021-11-01